pasireotide: Clinical Trials

8 trials of pasireotide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 unknown, 1 active not recruiting, 1 withdrawn. 8 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 48Completed 4, Unknown 2, Active not recruiting 1, Withdrawn 1

Follow pasireotide: new trials by email Literature Review of pasireotide trials Research Report on pasireotide

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Pasireotide 0.3 MG/ML, Meal tolerance test (MTT) - Hypoglycemia, Reactive
Phase 4UnknownZealand University Hospital52018-06-012018-07-05
HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications
Hydrocortisone, Pasireotide - Pancreatic Fistula, Pancreatic Neoplasms
Phase 4Active not recruitingHelsinki University Central Hospital1262016-05-012020-08-24
Pasireotide Treatment for Neuroendocrine Tumor
Pasireotide, Diazoxide - Gastro-enteropancreatic Neuroendocrine Tumor
Phase 4WithdrawnUniversity of Maryland, Baltimore2016-04-012022-03-04
Treatment of Hypoglycemia Following Gastric Bypass Surgery
Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil) - Hypoglycemia, Obesity
Phase 4CompletedZealand University Hospital112015-10-012018-03-07
Pasireotide LAR and Pegvisomant Study in Acromegaly
Pasireotide LAR 60 mg, Pegvisomant - Acromegaly
Phase 4UnknownErasmus Medical Center602015-08-012016-08-03
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Pasireotide s.c., Sitagliptin, Liraglutide - Cushing's Disease, Acromegaly
Phase 4CompletedNovartis Pharmaceuticals2492014-05-232019-05-29
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
Pasireotide, Cabergoline, Pasireotide LAR - Cushing's Disease, Acromegaly
Phase 4CompletedRECORDATI GROUP3372013-06-102024-10-01
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
Pasireotide 0.6 MG/ML - Cushing Disease
Phase 4CompletedUniversity of Palermo242013-05-012017-10-27

Conditions studied

Acromegaly (3)  ·  Hypoglycemia (3)  ·  Pituitary ACTH Hypersecretion (3)  ·  Dumping Syndrome (1)  ·  Gastro-enteropancreatic neuroendocrine tumor (1)  ·  Hyperglycemia (1)  ·  Hyperinsulinism (1)  ·  Melanoma (1)  ·  Neoplasms (1)  ·  Neuroendocrine Tumors (1)  ·  Obesity (1)  ·  Pancreatic Fistula (1)  ·  Pancreatic Neoplasms (1)  ·  Pituitary Neoplasms (1)  ·  Prostatic Neoplasms (1)

Sponsors

Zealand University Hospital (2)  ·  Erasmus Medical Center (1)  ·  Helsinki University Central Hospital (1)  ·  Novartis Pharmaceuticals (1)  ·  RECORDATI GROUP (1)  ·  University of Maryland, Baltimore (1)  ·  University of Palermo (1)

Countries

Belgium (2)  ·  Brazil (2)  ·  Denmark (2)  ·  Germany (2)  ·  India (2)  ·  Netherlands (2)  ·  Peru (2)  ·  Poland (2)  ·  Russia (2)  ·  Thailand (2)  ·  Turkey (Türkiye) (2)  ·  United States (2)  ·  Argentina (1)  ·  Bulgaria (1)  ·  Canada (1)

Top investigators

Caroline C Gormsen, M.D. (1)  ·  Kashif M Munir, MD (1)  ·  Sebastian Neggers, MD PhD (1)

Results publications

PMID 27405306, PMID 29155991, PMID 31907828, PMID 32022887, PMID 34275099

NIH funding

2014 (1)